Breaking News, Collaborations & Alliances

Exothera Forms Vaccine Manufacturing Partnership with Vaccizone

The CDMO will provide process development and GMP manufacturing of Vaccizone’s SARS-CoV-2 vaccine.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Vaccizone, a vaccine development company focusing on innovative antigen delivery technology, selected the contract development and manufacturing organization (CDMO) Exothera S.A. to fast-track process development of its SARS‑CoV‑2 vaccine for European clinical trials. Vaccizone has developed and patented a novel method for delivering antigens and bioactive compounds which can increase the stability and shelf life of complex biotherapeutics, like vaccines, monoclonal antibodies and cell and ge...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters